Arrowhead Research | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Agios Pharmaceuticals USD 9.47M 1.29M 2024-12
Alnylam Pharmaceuticals USD 490.35M 75.33M 2024-12
Arrowhead Research -173085000 2.55M 2024-12
Incyte USD 1.1B 38.34M 2024-12
Ionis Pharmaceuticals USD 222.75M 90M 2024-12
Ligand Pharmaceuticals USD 39.98M 9.39M 2024-12
Merck USD 11.92B 852M 2024-12
Moderna USD 420M 1.14B 2024-12
Novartis USD 10.23B 294M 2024-12
Sarepta Therapeutics USD 526.11M 150.63M 2024-12
TG Therapeutics USD 92.79M 18.25M 2024-12
Ultragenyx Pharmaceutical USD 147.98M 29.51M 2024-12
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12
Xencor -45143000 40.69M 2024-09



Arrowhead Research Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.